Peter P. Toth – författare

Lipid management is a key part of medical practice, affecting the prevention and treatment of several diseases, including diabetes, cardiovascular disease and stroke. A practical text on the clinical management of dyslipidemias, Practical Lipid Management balances conceptual development and pathophysiology with a straightforward approach to the identification and treatment of abnormalities in lipid metabolism.The book explores the role of novel risk markers in clinical practice, summarizes the current guidelines for lipid management, and offers a critical and systematic approach to interpreting the results of clinical trials. A feature of the book is a set of sidebars which explore current controversies and unanswered questions in clinical lipidology. The treatment of specific dyslipidemias is illustrated with case studies. Treatment algorithms are also provided.Practical Lipid Management: details the relationship between specific lipids, lipoproteins and cardiovascular disease,provides guidance on the etiology and diagnosis of lipid abnormalities,summarizes current understanding of atherogenesis, andreviews the evidence base for the use of therapeutic lifestyle change and specific lipid-lowering medications to reduce morbidity and mortality from cardiovascular disease.Practical Lipid Management provides a concise summary of best practice according to various international guidelines, making it a useful tool for all primary care physicians and others involved in the management of diseases such as diabetes, cardiovascular disease and stroke. It will serve as an evidence-based, rapid, and valuable resource for family physicians, internists, nurse practitioners, physician assistants, cardiologists, endocrinologists and allied health professionals involved in the care of patients with lipid disorders.

Filling a large gap in the literature, this book focuses on the management of patients who have, or are at risk of developing, cardiovascular disease. Designed to serve as a resource for the busy, practicing clinician, the approach is evidence-based but practical. Conceptual development and the exploration of biochemical and physiological mechanisms are balanced by focused attention on the everyday issues of caring for patients with specific metabolic and cardiovascular disorders. Reinforced by case studies, the book discusses standards of care and challenging management issues. The authors discuss pharmacotherapeutic choices in light of findings from clinical trials, elements of care unique to women and people of different racial and ethnic groups, lifestyle modifications, and the risks and benefits of specific therapies. The book reviews comprehensive care in both primary and secondary prevention settings. Moreover, Comprehensive Management of High Risk Cardiovascular Patients encourages primary care providers to get more involved in treating such disorders as atherosclerotic disease, congestive heart failure, severe hypertension, complex dyslipidemias, and chronic renal disease, among others.

Chronic overconsumption of sugar and fat elevates plasma levels of insulin and free fatty acids, a process referred to as glucolipotoxicity. This phenomenon may lead to heart failure. This issue explores in depth the relationship between glucolipotoxicity and heart failure.

Authoritative and comprehensive, Lipoproteins in Diabetes Mellitus details the many changes wrought by insulin resistance and diabetes mellitus on lipid and lipoprotein metabolism.

Since the creation of the American Board of Clinical Lipidology, many clinicians have wanted an up-to-date, comprehensive reference on lipidology.

Comprehensive Cardiovascular Medicine in the Primary Care Setting provides an authoritative, detailed discussion of cardiovascular disease balanced with practical utility.

This second edition provides an updated review on the current guidelines and practice standards for the clinical management of cardiovascular risk factors and prevention of cardiovascular diseases.

The second edition of this important book provides an up-to-date and comprehensive overview of clinical lipidology. Brand new chapters focus on recent advances in the field including novel biomarkers and the microbiome, genomics of cardiovascular risks, PCSK9 inhibitors, imaging technologies, and epidemiology of atherosclerotic cardiovascular disease.The book describes new guidelines, novel therapeutic agents, and changes in the understanding of specific lipoproteins and subclasses with regard to their relationships to cardiovascular disease risk. The second edition contains more than thirty chapters covering such topics as the history of lipidology, lipoprotein metabolism and vascular biology, disorders of lipid metabolism, lifestyle/dietary and pharmacologic management for dyslipidemia, the management of dyslipidemia in certain subgroups (e.g., women, children, older patients) and lipid testing, as well as an examination of other biomarkers and testing procedures related toatherosclerosis and cardiovascular disease. The second edition of Therapeutic Lipidology is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.

The second edition of this important book provides an up-to-date and comprehensive overview of clinical lipidology. Brand new chapters focus on recent advances in the field including novel biomarkers and the microbiome, genomics of cardiovascular risks, PCSK9 inhibitors, imaging technologies, and epidemiology of atherosclerotic cardiovascular disease.The book describes new guidelines, novel therapeutic agents, and changes in the understanding of specific lipoproteins and subclasses with regard to their relationships to cardiovascular disease risk. The second edition contains more than thirty chapters covering such topics as the history of lipidology, lipoprotein metabolism and vascular biology, disorders of lipid metabolism, lifestyle/dietary and pharmacologic management for dyslipidemia, the management of dyslipidemia in certain subgroups (e.g., women, children, older patients) and lipid testing, as well as an examination of other biomarkers and testing procedures related toatherosclerosis and cardiovascular disease. The second edition of Therapeutic Lipidology is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.

Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for cardiovascular vascular disease.  Data from case control, epigenetic and mendelian randomization studies indicate that people with elevated Lp(a) have a two-fold to four-fold increased risk of cardiovascular events compared to people with low Lp(a) levels. Despite this risk, awareness of Lp(a) is still very low among health care providers. Even cardiologists often overlook Lp(a), in part because Lp(a) is not as well-understood as other risk factors and treatment options are still very limited.  This book offers an authoritative and comprehensive overview of Lipoprotein(a). It provides an in-depth review of all aspects of Lp(a), from pathophysiology to metabolism. Chapters offer the reader a contemporary view of the important roles of Lp(a) as a risk factor for cardiovascular disease. In addition, this volume discusses the clinical implications of elevated Lp(a) and current and future therapies.  Lipoprotein(a) is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.

Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for cardiovascular vascular disease.  Data from case control, epigenetic and mendelian randomization studies indicate that people with elevated Lp(a) have a two-fold to four-fold increased risk of cardiovascular events compared to people with low Lp(a) levels. Despite this risk, awareness of Lp(a) is still very low among health care providers. Even cardiologists often overlook Lp(a), in part because Lp(a) is not as well-understood as other risk factors and treatment options are still very limited.  This book offers an authoritative and comprehensive overview of Lipoprotein(a). It provides an in-depth review of all aspects of Lp(a), from pathophysiology to metabolism. Chapters offer the reader a contemporary view of the important roles of Lp(a) as a risk factor for cardiovascular disease. In addition, this volume discusses the clinical implications of elevated Lp(a) and current and future therapies.  Lipoprotein(a) is an essential resource for physicians, medical students, residents, fellows, and allied health professionals in lipidology, cardiology, endocrinology, pharmacotherapy, and health promotion and disease prevention.

New topicsinclude the links between glycemia and lipoproteins, the role of lipoproteins in ischemic stroke, the diagnosis and management of statin intolerance (which is thought to be more common in people with diabetes) and the use of PCSK9 inhibitors and fish oils in the management of lipoproteins in people with diabetes.

New topicsinclude the links between glycemia and lipoproteins, the role of lipoproteins in ischemic stroke, the diagnosis and management of statin intolerance (which is thought to be more common in people with diabetes) and the use of PCSK9 inhibitors and fish oils in the management of lipoproteins in people with diabetes.

This book is a unique, comprehensive board review dedicated solely to preventive cardiology. This volume is a companion work to the ASPC Manual of Preventive Cardiology. The book is comprised of a series of questions, each which addresses a core issue in preventive cardiology. Each question is accompanied with a correct answer key as well as a discussion of why the chosen response is correct, and the others are incorrect. Answers are supported by illustrations and discussion of contemporary literature when applicable. The book also provides references for additional study. This book contains questions written by many of the original authors who contributed to the ASPC Manual of Preventive Cardiology. This book, along with the ASPC Manual of Preventive Cardiology, accompanies the ASPC Experts Course in Preventive Cardiology.The ASPC Self-Assessment Program in Preventive Cardiology is a valuable resource for cardiologists and other specialists, as well as primary care clinicians (including internists, family physicians, nurse practitioners, and physician assistants) who seek additional training and expertise in cardiovascular disease prevention.